BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 27685140)

  • 1. Accuracy of one algorithm used to modify a planned DVH with data from actual dose delivery.
    Ma T; Podgorsak MB; Kumaraswamy LK
    J Appl Clin Med Phys; 2016 Sep; 17(5):273-282. PubMed ID: 27685140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of DVH-based plan verification methods for VMAT: ArcCHECK-3DVH system and dynalog-based dose reconstruction.
    Saito M; Kadoya N; Sato K; Ito K; Dobashi S; Takeda K; Onishi H; Jingu K
    J Appl Clin Med Phys; 2017 Jul; 18(4):206-214. PubMed ID: 28649722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial experience of ArcCHECK and 3DVH software for RapidArc treatment plan verification.
    Infusino E; Mameli A; Conti R; Gaudino D; Stimato G; Bellesi L; D'Angelillo RM; Ramella S; Benassi M; Trodella L
    Med Dosim; 2014; 39(3):276-81. PubMed ID: 25088815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3D DVH-based metric analysis versus per-beam planar analysis in IMRT pretreatment verification.
    Carrasco P; Jornet N; Latorre A; Eudaldo T; Ruiz A; Ribas M
    Med Phys; 2012 Aug; 39(8):5040-9. PubMed ID: 22894429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DVH analysis using a transmission detector and model-based dose verification system as a comprehensive pretreatment QA tool for VMAT plans: Clinical experience and results.
    Mohamed Yoosuf AB; AlShehri S; Alhadab A; Alqathami M
    J Appl Clin Med Phys; 2019 Nov; 20(11):80-87. PubMed ID: 31605456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing measurement-derived (3DVH) and machine log file-derived dose reconstruction methods for VMAT QA in patient geometries.
    Tyagi N; Yang K; Yan D
    J Appl Clin Med Phys; 2014 Jul; 15(4):4645. PubMed ID: 25207396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A clinically relevant IMRT QA workflow: Design and validation.
    Stambaugh C; Ezzell G
    Med Phys; 2018 Apr; 45(4):1391-1399. PubMed ID: 29481698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using a novel dose QA tool to quantify the impact of systematic errors otherwise undetected by conventional QA methods: clinical head and neck case studies.
    Chan MF; Li J; Schupak K; Burman C
    Technol Cancer Res Treat; 2014 Feb; 13(1):57-67. PubMed ID: 23819494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dosimetric evaluation of MapCHECK 2 and 3DVH in the IMRT delivery quality assurance process.
    Song JY; Kim YH; Jeong JU; Yoon MS; Ahn SJ; Chung WK; Nam TK
    Med Dosim; 2014; 39(2):134-8. PubMed ID: 24332483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A method to reconstruct and apply 3D primary fluence for treatment delivery verification.
    Liu S; Mazur TR; Li H; Curcuru A; Green OL; Sun B; Mutic S; Yang D
    J Appl Clin Med Phys; 2017 Jan; 18(1):128-138. PubMed ID: 28291913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pretreatment patient-specific IMRT quality assurance: a correlation study between gamma index and patient clinical dose volume histogram.
    Stasi M; Bresciani S; Miranti A; Maggio A; Sapino V; Gabriele P
    Med Phys; 2012 Dec; 39(12):7626-34. PubMed ID: 23231310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitivity of volumetric modulated arc therapy patient specific QA results to multileaf collimator errors and correlation to dose volume histogram based metrics.
    Coleman L; Skourou C
    Med Phys; 2013 Nov; 40(11):111715. PubMed ID: 24320423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvements in treatment planning calculations motivated by tightening IMRT QA tolerances.
    Stambaugh C; Gagneur J; Uejo A; Clouser E; Ezzell G
    J Appl Clin Med Phys; 2019 Jan; 20(1):250-257. PubMed ID: 30599085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinically relevant quality assurance (QA) for prostate RapidArc plans: gamma maps and DVH-based evaluation.
    Cozzolino M; Oliviero C; Califano G; Clemente S; Pedicini P; Caivano R; Chiumento C; Fiorentino A; Fusco V
    Phys Med; 2014 Jun; 30(4):462-72. PubMed ID: 24480527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dependency of planned dose perturbation (PDP) on the spatial resolution of MapCHECK 2 detectors.
    Keeling VP; Ahmad S; Algan O; Jin H
    J Appl Clin Med Phys; 2014 Jan; 15(1):4457. PubMed ID: 24423843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantification of residual dose estimation error on log file-based patient dose calculation.
    Katsuta Y; Kadoya N; Fujita Y; Shimizu E; Matsunaga K; Matsushita H; Majima K; Jingu K
    Phys Med; 2016 May; 32(5):701-5. PubMed ID: 27162084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Moving from gamma passing rates to patient DVH-based QA metrics in pretreatment dose QA.
    Zhen H; Nelms BE; Tome WA
    Med Phys; 2011 Oct; 38(10):5477-89. PubMed ID: 21992366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of direct clinical consequences of MLC positional errors in volumetric-modulated arc therapy using 3D dosimetry system.
    Nithiyanantham K; Mani GK; Subramani V; Mueller L; Palaniappan KK; Kataria T
    J Appl Clin Med Phys; 2015 Sep; 16(5):296–305. PubMed ID: 26699311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utilizing knowledge from prior plans in the evaluation of quality assurance.
    Stanhope C; Wu QJ; Yuan L; Liu J; Hood R; Yin FF; Adamson J
    Phys Med Biol; 2015 Jun; 60(12):4873-91. PubMed ID: 26056801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of patient DVH-based QA metrics for prostate VMAT: correlation between accuracy of estimated 3D patient dose and magnitude of MLC misalignment.
    Kadoya N; Saito M; Ogasawara M; Fujita Y; Ito K; Sato K; Kishi K; Dobashi S; Takeda K; Jingu K
    J Appl Clin Med Phys; 2015 May; 16(3):5251. PubMed ID: 26103486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.